# EndoPredict® Extended Endocrine Trial (EXET)

> **NCT04016935** · — · TERMINATED · sponsor: **Myriad Genetic Laboratories, Inc.** · enrollment: 855 (actual)

## Conditions studied

- Primary Invasive Breast Cancer

## Interventions

- **OTHER:** Observational

## Key facts

- **NCT ID:** NCT04016935
- **Lead sponsor:** Myriad Genetic Laboratories, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-02
- **Primary completion:** 2022-03-31
- **Final completion:** 2022-03-31
- **Target enrollment:** 855 (ACTUAL)
- **Why stopped:** It was determined that we had sufficient enrollment and study data to explore the impact of the Endopredict test in endocrine therapy decision-making.
- **Last updated:** 2022-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04016935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04016935, "EndoPredict® Extended Endocrine Trial (EXET)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04016935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*